Skip to content
Resources > Reports

AI in Drug Development 2026: From Experimentation to Execution

By Sara Mallatt, Director of Healthcare Research and Sean Carmichael, Senior Business & Finance Editor

AI has advanced from pilot programs into real biopharma workflows. But has it lived up to the hype? Drawing from an expert call with Dr. Paul Agapow, former director of data science at GSK, this report dissects whether AI is on track to make drug development faster, cheaper, and more successful. Learn how AI is reshaping drug development in real time, turning AI execution into a key competitive differentiator.

About the Authors
  • Sara Mallatt

    Sara Mallatt, Director of Healthcare Research

    Sara has more than 18 years of experience generating sell-side research content across a variety of industries. Prior to joining AlphaSense, Sara held leadership positions at OTR Global, a leading channel research firm, most recently as Director of Healthcare Research. Sara holds a bachelor’s degree in journalism and a master’s in industrial engineering. She works from her home in Missoula, Montana.
  • Sean Carmichael

    Sean Carmichael, Senior Business & Finance Editor

    Sean is a Senior Business & Finance Editor at AlphaSense, specializing in sector-specific content production. Previously, he spent nearly a decade in various roles across financial services, where he was responsible for equity research and content generation geared toward institutional investors.

Explore more

All articles

How Family Offices Are Leveraging Trusted AI at Scale

While AI adoption is widespread among institutional investors, only 22% of family offices use AI with regularity. Data privacy and trustability largely remain barriers to adoption.
ReportAI
How Family Offices Are Leveraging Trusted AI, with an isometric line drawing of an office desk and chair.

Security, Privacy & Trust in the Age of AI

In this report, discover the foundational questions and principles that firms should be requiring of AI providers as they prioritize scaling trustworthy AI infrastructure.
Report
Cover graphic titled Security, Privacy and Trust in the Age of AI, by Lawrence Sica, VP of Product Security, with line icons of a folder, an eye, a padlock, and a shield

Top AI Use Cases for Investor Relations

The AI era has ushered in a new reality for investor relations. Discover how the leading IR teams are harnessing AI to unify peer tracking, sentiment analysis, and real-time market monitoring into a single intelligence layer.
Report
Title: Top AI Use Cases for Investor Relations. Blue isometric illustration shows a shield with a checkmark, binoculars, and a filing cabinet.

Transform intelligence
into advantage

Develop bold strategies, seize opportunities,
and lead with clarity and confidence.